NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Climb Bio, Inc. (CLYM) Stock Analysis

Climb Bio, Inc. (CLYM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CLYM

$10.87

+$0.07 (+0.65%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLYM with… →

CLYM Key Statistics

As of Oct 21, 2026
Trading
Open
$10.60
Previous Close
$10.80
Day's Range
10.60–11.26
52-Week Range
1.64–18.33
Volume
930.39K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.03
Valuation
Market Cap
$592.17M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.82
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$59.85M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
57.44M
1-Year Return
+380.97%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
1.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CLYM closed at $10.87, +380.97% over 1 year.

Climb Bio, Inc. (CLYM) has a market capitalization of $592.17M.

In fiscal 2025, CLYM reported revenue of $0.00.

CLYM Stock Return by Calendar Year

Climb Bio, Inc. (CLYM) return since Aug 2021: what $10,000 became

1 year
$10,000 $48,097
+380.97%
5 years
$10,000 $6,187
−38.13%
Since Aug 2021
$10,000 $6,836
−31.64%

If you had invested $10,000 in Climb Bio, Inc. (CLYM) at the close on August 10, 2021, the earliest close on record here, it would have been worth $6,836 at the close on October 21, 2026: −31.64% in total, −7.06% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+171.75%
2025+122.22%
2024−33.33%
2023−26.43%
2022−64.91%
2021 (partial year)−34.21%

As of October 21, 2026.

CLYM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$59.85M—
2024$0.00−$73.90M—
2023$0.00−$35.12M—
2022$0.00−$45.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$67.88M−$59.85M—
2024$0.00—−$30.36M−$73.90M—
2023$0.00—−$40.28M−$35.12M—
2022$0.00—−$45.14M−$45.24M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Climb Bio, Inc. (CLYM) is capitalised at $592.17M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 28 employees.

CLYM last closed at $10.87 on October 21, 2026. That is +$0.07 (+0.65%) against the previous close. Over the past 52 weeks the price has ranged from $1.64 to $18.33. The latest close sits 564.83% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $59.85M. Trailing earnings per share are −0.82.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +380.97%. Across 5 years the annualized return works out at −9.16%. Beta against the wider market is reported at −0.03. Annualized volatility over the trailing 5 years is 104.38%.

Growth & Income

The record shows no dividend for CLYM.

So far in 2026 the total return is +171.75%. The strongest complete calendar year on file is 2025 at +122.22%; the weakest is 2022 at −64.91%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Climb Bio, Inc. (CLYM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Climb Bio, Inc. CLYM $592.17M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Climb Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Climb Bio, Inc.

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Visit website →